Value
7.7/10data confidence 100%| Component | Sub-score |
|---|---|
| P/E | 8.5 |
| P/S | 9.6 |
| EV/EBITDA | 6.7 |
| Fwd P/E | 9.2 |
| PEG | 10.0 |
| Analyst target | 3.0 |
- ▸Forward P/E: 10.7x
- ▸PEG: 0.21
- ▸Attractively valued
MD · Why this verdict
Why Pediatrix Medical Group (MD) is rated BUY WAIT
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictBUY WAIT
Overall score5.7/10
ConfidenceMEDIUM
MacroNEUTRAL
TrendMatrix Research · core thesis
Engine thesis — one sentence
Pediatrix trades at a low forward multiple of 10.3x with a PEG of 0.21 and peer-leading margins, but deeply overbought conditions at an RSI of 90, a stock price already above the technical resistance target, and a recent officer-level change create a poor setup for new buyers despite the fundamental appeal.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
A forward price-to-earnings multiple of 10.3x alongside a PEG ratio of 0.21 suggests the market is pricing in conservative growth expectations, creating room for re-rating if the company continues to grow earnings faster than consensus anticipates. Valuation breakdown | Forward earnings estimates are revised upward by at least 10% over the next 12 months, reducing the already-low multiple further and attracting value-oriented buyers. | Tripped→Stable |
| CounterA low PEG can persist in healthcare services businesses facing reimbursement-rate headwinds or volume sensitivity; if revenue growth stalls, the earnings growth assumption underpinning the low PEG collapses. | ||
Three of the past four quarters delivered positive earnings surprises averaging approximately 19%, but the quarter ending February 2026 resulted in a 7% miss — leaving the beat track record solid but with one unresolved blemish in the recent set. Earnings | The next two quarterly results each beat consensus, restoring a clean beat pattern and removing the overhang from the prior miss. | ↓Deteriorating |
| CounterThe single miss may signal an emerging structural pressure on earnings reliability rather than a one-off; if the next quarter also misses, the beat narrative loses its foundation. | ||
The stock's RSI has reached 90 — a deeply overbought reading — while the price has extended past the technical resistance target, leaving minimal reward relative to the risk of mean reversion. Momentum breakdown | RSI retreats toward 60 or below over the next two to three months, allowing the price to consolidate and reset the entry point without a sharp drawdown. | ↑Improving |
| CounterOverbought conditions can persist for extended periods in small-cap healthcare names with positive operating momentum; a strong upcoming earnings print could justify the elevated reading and push the price even higher. | ||
A recent officer-level departure or appointment has been disclosed in a regulatory filing, introducing a period of uncertainty around management continuity at a company where clinical and operational leadership is central to service quality. Gates warning | No additional senior leadership changes are announced over the next three to four quarters, and the team demonstrates operational continuity through consistent financial results. | →Stable |
| CounterSingle leadership changes are routine in healthcare services and do not necessarily disrupt operations; an incoming leader with relevant sector experience could prove a net positive for strategic direction. | ||
A forward price-to-earnings multiple of 10.3x alongside a PEG ratio of 0.21 suggests the market is pricing in conservative growth expectations, creating room for re-rating if the company continues to grow earnings faster than consensus anticipates.
Tripped→StableValuation breakdown
- Expectation
- Forward earnings estimates are revised upward by at least 10% over the next 12 months, reducing the already-low multiple further and attracting value-oriented buyers.
CounterA low PEG can persist in healthcare services businesses facing reimbursement-rate headwinds or volume sensitivity; if revenue growth stalls, the earnings growth assumption underpinning the low PEG collapses.
Three of the past four quarters delivered positive earnings surprises averaging approximately 19%, but the quarter ending February 2026 resulted in a 7% miss — leaving the beat track record solid but with one unresolved blemish in the recent set.
↓DeterioratingEarnings
- Expectation
- The next two quarterly results each beat consensus, restoring a clean beat pattern and removing the overhang from the prior miss.
CounterThe single miss may signal an emerging structural pressure on earnings reliability rather than a one-off; if the next quarter also misses, the beat narrative loses its foundation.
The stock's RSI has reached 90 — a deeply overbought reading — while the price has extended past the technical resistance target, leaving minimal reward relative to the risk of mean reversion.
↑ImprovingMomentum breakdown
- Expectation
- RSI retreats toward 60 or below over the next two to three months, allowing the price to consolidate and reset the entry point without a sharp drawdown.
CounterOverbought conditions can persist for extended periods in small-cap healthcare names with positive operating momentum; a strong upcoming earnings print could justify the elevated reading and push the price even higher.
A recent officer-level departure or appointment has been disclosed in a regulatory filing, introducing a period of uncertainty around management continuity at a company where clinical and operational leadership is central to service quality.
→StableGates warning
- Expectation
- No additional senior leadership changes are announced over the next three to four quarters, and the team demonstrates operational continuity through consistent financial results.
CounterSingle leadership changes are routine in healthcare services and do not necessarily disrupt operations; an incoming leader with relevant sector experience could prove a net positive for strategic direction.
Per-dimension breakdown
Quality
5.3/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 6.8 |
| ROA | 4.7 |
| Gross margin | 1.2 |
| Op margin | 5.4 |
| Net margin | 4.5 |
| Current ratio | 4.9 |
| FCF quality | 6.6 |
| Moat | 5.6 |
| Piotroski F | 7.8 |
- ▸Strong Piotroski F-Score: 7/9
Growth
3.4/10data confidence 67%| Component | Sub-score |
|---|---|
| Rev growth | 3.5 |
| EPS growth | 3.3 |
Momentum
5.9/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 5.5 |
| MACD | 2.8 |
| OBV | 10.0 |
| MA position | 9.0 |
| Volume | 2.1 |
- ▸Volume accumulation (rising OBV)
- ▸Above 200-day MA
Sentiment
6.2/10data confidence 100%| Component | Sub-score |
|---|---|
| LLM sentiment | 7.0 |
| Analyst rating | 6.6 |
| Price target | 4.8 |
- ▸LLM news sentiment: +0.40 (n=1)
- ▸Light analyst coverage (6.0) — signal dampened
Insider
7.3/10data confidence 75%| Component | Sub-score |
|---|---|
| materiality | 5.0 |
| holder change | 10.0 |
| notable moves | 7.0 |
- ▸No net insider activity — $0 (0.000% of mkt cap)
- ▸Institutions accumulating
Peer rank
5.3/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 6.2 |
| quality rank | 6.8 |
| growth rank | 3.0 |
Technical
4.8/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 3.5 |
| support resistance | 1.8 |
| 52w position | 9.0 |
Risk (lower is worse)
4.2/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 6.4 |
| days to cover | 5.0 |
| volatility | 1.8 |
| put call | 0.0 |
| implied vol | 0.2 |
| beta | 9.1 |
| debt equity | 6.8 |
- ▸Elevated put/call: 100.83
- ▸High IV: 79%
Catalyst
6.3/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 6.7 |
| earnings timing | 5.0 |
| surprise avg | 9.9 |
| news activity | 5.0 |
- ▸Strong earnings: 3B/1M
How the verdict was assembled
Engine trigger
Maintain position. Not compelling to add more. | News modifier +2 (HOLD_IF_HOLDING → STRONG_BUY_WAIT).
Engine technical detail
verdict_path:
L4:PATH_F_HOLD|L3:NEWS_MOD=+2|ENTRY_STICKY:PRIOR_STILL_VIABLEPassed (6)
- MOMENTUM:5.9>=5.5
- INSIDER:OK
- NEWS_BOOST:ANALYST:0.40
- EARNINGS_PROXIMITY:81d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (1)
- ASYMMETRY:-1.0=NEGATIVE
Warning (1)
- 8K_CSUITE_CHANGE:5.02 (officer departure/appointment)
Reward-to-Risk
-0.96
Upside
-14.1%
Downside
14.7%
Sizing output
STARTER
SetupRange Bound — RSI 56 mid-range, Bollinger mid-band
EdgeNo clear edge — No clear edge identified
SuitabilityAggressive — MCap $2.1B<$5B
Investment implication
None of the engine's positive-conviction paths (C-quality, D-momentum) triggered — the F-path HOLD reflects balanced signals. Strongest-cleared gate: MOMENTUM:5.9>=5.5. Top dim: Value at 7.7; weakest: Growth at 3.4. No conviction either direction.
The strongest dimensions are Value at 7.7, Insider at 7.3, and Catalyst at 6.3; the weakest are Growth at 3.4, Risk (lower is worse) at 4.2, and Technical at 4.8. The V9 engine flagged 1 failed gate with 1 warning, producing an asymmetric reward-to-risk of -0.96 and an engine sizing output of STARTER.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Compelling Fundamental ValuationTripped
Trip ifForward P/E expands above 18x as price appreciation outpaces earnings growth, closing the fundamental value gap.
- P2Earnings Momentum With Recent Stumble
Trip ifEPS surprise falls below 0% for 2 consecutive quarters, reversing the earnings-beat trend.
- P3Severely Overbought Above Resistance
Trip ifAnalyst consensus price target is revised upward by more than 20%, restoring meaningful upside relative to the current price level.
- P4Management Transition Uncertainty
Trip ifThe incoming leader remains in role for more than 4 consecutive quarters with no further C-suite 8-K disclosures, confirming management stability has been restored.